NASDAQ:ZFGN - Zafgen Stock Price, Forecast & News

Zafgen trades on the NASDAQ under the ticker symbol "ZFGN."

Zafgen Inc (NASDAQ:ZFGN) released its earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.03. View Zafgen's Earnings History.

Zafgen is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Zafgen.

7 brokers have issued 12-month target prices for Zafgen's shares. Their forecasts range from $0.78 to $17.00. On average, they anticipate Zafgen's stock price to reach $7.06 in the next twelve months. This suggests a possible upside of 524.8% from the stock's current price. View Analyst Price Targets for Zafgen.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zafgen in the last year. There are currently 5 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Zafgen.

Media coverage about ZFGN stock has trended extremely negative on Sunday, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Zafgen earned a daily sentiment score of -4.5 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Zafgen.

Zafgen saw a decrease in short interest in December. As of December 31st, there was short interest totalling 520,800 shares, a decrease of 9.8% from the December 15th total of 577,500 shares. Based on an average daily volume of 687,800 shares, the days-to-cover ratio is presently 0.8 days. Approximately 1.6% of the shares of the stock are short sold. View Zafgen's Current Options Chain.

Some companies that are related to Zafgen include Harrow Health (HROW), Arcturus Therapeutics (ARCT), Monopar Therapeutics (MNPR), Ovid Therapeutics (OVID), ContraFect (CFRX), Akorn (AKRX), Corvus Pharmaceuticals (CRVS), TAIWAN LIPOSOME/S (TLC), Strongbridge Biopharma (SBBP), Mustang Bio (MBIO), Aldeyra Therapeutics (ALDX), Adamas Pharmaceuticals (ADMS), PhaseBio Pharmaceuticals (PHAS), NuCana (NCNA) and Galectin Therapeutics (GALT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Zafgen investors own include CA (CA), Endologix (ELGX), Energy Transfer LP Unit (ET), TG Therapeutics (TGTX), BlackRock (BLK), Fate Therapeutics (FATE), Gilead Sciences (GILD), Micron Technology (MU), SCYNEXIS (SCYX) and AT&T (T).

Zafgen's stock is owned by a number of of institutional and retail investors. Top institutional investors include Wedbush Securities Inc. (0.23%). View Institutional Ownership Trends for Zafgen.

ZFGN stock was sold by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. View Insider Buying and Selling for Zafgen.

Shares of ZFGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ZFGN stock can currently be purchased for approximately $1.13.

Zafgen has a market capitalization of $42.23 million. The biopharmaceutical company earns $-61,370,000.00 in net income (profit) each year or ($1.90) on an earnings per share basis. Zafgen employs 38 workers across the globe.View Additional Information About Zafgen.

The official website for Zafgen is http://www.zafgen.com/.

Zafgen's mailing address is 3 Center Plaza Suite 610, BOSTON MA, 02108. The biopharmaceutical company can be reached via phone at 617-622-4003 or via email at [email protected]